Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Germany / NCT07597018
Recruiting Phase 1

A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity

NCT07597018 · tracked via the Priya Life Science Germany tracker
Sponsor
Novo Nordisk A/S
Phase
Phase 1
Started
2026-05-18
Last updated
2026-06-26

Condition(s) studied

ObesityOverweight

Investigational drug(s) / intervention(s)

Cagrilintide DCagrilintide B and placebo semaglutide I

Cagrilintide D: Cagrilintide D will be administered subcutaneously.

Cagrilintide B and placebo semaglutide I: Cagrilintide B and placebo semaglutide I will be administered subcutaneously

Study summary

This clinical study is testing two versions of the study medicine cagrilintide. The purpose of the study is to compare these two versions to understand their effects in participants with overweight or obesity. Participants will receive either cagrilintide version D or cagrilintide version B, and which treatment participants receive is decided by chance. Participants will be in this clinical study for about 6 months.

Eligibility

Sex
ALL
Min age
18 Years
Max age
64 Years
Healthy volunteers
No
Inclusion Criteria: * Aged 18-64 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 27.0 and 34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator. * Considered to be generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram (ECG), and clinical laboratory tests performed during the screening visit, as judged by the investigator. Exclusion Criteria: * Previous participation in study(s) with an amylin analogue. Participation is defined as randomisation. * Any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol.

Primary outcome measure(s)

  • AUC,ss: area under the total cagrilintide concentration-time curve at steady state after 5th dosing of cagrilintide s.c. — Day 113 (pre-dose) to Day 120 (post-dose)
    Measured in hour nanomoles per litre (h\*nmol/L)
  • Cmax,ss: maximum concentration of total cagrilintide at steady state after 5th dosing of cagrilintide s.c. — Day 113 (pre-dose) to Day 120 (post-dose)
    Measured in nanomoles per litre (nmol/L).

Trial sites (1)

FacilityCityRegionStatus
Parexel International GmbH Berlin Germany Recruiting

More Novo Nordisk A/S trials in Germany

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A Active, not recruiting
A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes Active, not recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Active, not recruiting
Influence of Adherence to Growth Hormone Therapy (GHT) With Norditropin® on Near Final Height in Patients With Growth Hormone Deficiency (GHD) and Born Small for Gestational Age (SGA) Enrolling by invitation
A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity Recruiting

Other trials for the same condition

A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes Starting soon
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity Recruiting
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight Active, not recruiting
Deep Phenotyping of Peripheral Blood Cells and Circulating Factors in Metabolic Diseases Recruiting
A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07597018 on ClinicalTrials.gov ↗ ← All trials in Germany